Achilles Therapeutics PLC. Headquarters: U.K. The cell therapy player Achilles went public in early 2021, and its stock price has fallen by
The biotech stock market is in a tough spot right now, with many companies facing suppressed valuations. We've listed six public companies
Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years.
Are biotech companies trading at all-time lows?
Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years.
This downturn has led to many biotech firms trading below their cash holdings.
However, such scenarios can present compelling investment opportunities.
How much cash do biotech companies have?
The largest biopharma firms right now have almost enough cash to more or less buy every single small-to-mid-cap biotech company.
Yee calculates that the combined market capitalization of all the biotech stocks valued at under $5 billion is around $350 billion.
Right Now, Invitae's Cash Is Higher Than Its Market Cap
Taylor Carmichael (Invitae): The biotech market has been creamed in 2022, and Invitae stock is no exception.
This genomic biotech came public in February 2015.
The market got super excited about Invitae in 2020, and the stock reached an all-time high of $61 in December of that year.
Now the stock is at an all-time low of $3.52.
So we've gone from m.
The Device Maker in A Multi-Billion-Dollar Market
Patrick Bafuma (Singular Genomics): Life science technologycompany Singular Genomics not only fits the bill of having a market cap below its current assets ($216.7 million versus $325.8 million), but it has massive growth potential too.
Since it's targeting multi-billion-dollar markets, it won't take much for investors to reap serious rewards with .
Which biotech companies are trading below their cash reserves?
In this PRISM MarketView report, we spotlight 10 biotech companies trading below their cash reserves, set to experience impactful events in the next 3 to 6 months. 1.
Achilles Therapeutics Market Cap:
$35.21M as of October 24, 2023.
Cash:Cash and cash equivalents were $143.7 million as of June 30, 2023. Will biotechs run out of cash in 2022?
Jefferies analysts identified 18 biotechs at risk of running out of cash within a year.
Three of these companies also have substantial doubt about making it to the end of 2022.
The biotech market has continued to fall in 2022, with companies and investors prioritizing cash-saving measures to weather the storm.
